AlphaGrep UK
ALNY icon

AlphaGrep UK’s Alnylam Pharmaceuticals ALNY Stock Holding History

AlphaGrep UK’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-1,623
Closed -$489K – 735
2026
Q2 		$489K Buy
1,623
+662
+69% +$200K 0.15% 248
2026
Q1 		$318K Sell
961
-895
-48% -$305K 0.09% 477
2025
Q4 		$738K Buy
+1,856
New +$821K 0.25% 84

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

AlphaGrep UK's ALNY Position: Q3 2026 in Review

AlphaGrep UK sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2026, closing a stake of 1,623 shares — an estimated $489K sold.

AlphaGrep UK first reported a position in ALNY in Q4 2025 and held it in 3 quarters. The position peaked at $738K in Q4 2025. 591 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

  • AlphaGrep UK reported no remaining Alnylam Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • AlphaGrep UK sold 1,623 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $489K.
  • AlphaGrep UK first reported a position in Alnylam Pharmaceuticals in Q4 2025 and held it in 3 quarters.
  • AlphaGrep UK's Alnylam Pharmaceuticals position peaked at $738K in Q4 2025.
  • 591 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on AlphaGrep UK's 13F filing for Q3 2026, filed 12 Nov 2026.